Cenexi Acquires Schering-Plough Pharmaceutical Manufacturing Site

 
February 21, 2017

21 February 2017 / PARIS – Dechert LLP advised Cenexi, a manufacturing group of pharmaceuticals products, on its acquisition of a manufacturing site from Schering-Plough, a French subsidiary of the American group Merck Sharp & Dohme (MSD) which specializes in the manufacture and distribution of high value-added pharmaceuticals products. The site is located in Hérouville-Saint-Clair (Calvados, France).

This transaction allows Cenexi additional production capacities notably in sterile injectables, while also enhancing its leading market position as a contract development and manufacturing organization.

Founded in 2004 at Fontenay-sous-Bois, Cenexi is a manufacturing group of high value-added sterile pharmaceuticals products owned by Cathay Capital and management. Prior to Cathay Capital’s acquisition, Cenexi operated three manufacturing sites in France and Belgium and employed more than 900 people. Cathay Capital’s investment aimed to pursue Cenexi’s growth through selective acquisitions in France and internationally.

After having advised Cathay Capital, along with its founder Philippe Mougin and the managing team, in its purchase of majority stake in the Cenexi group in July 2015, Dechert LLP advised Cenexi in the context of this external growth operation. The team was led by corporate partner Isabelle Marguet, with support from corporate associates Xavier Leroux and Amira Mnafek, national regulatory partner Sophie Pelé, labor associate Thibault Meiers, as well as tax partner Bruno Leroy and tax associates Damien Fenard and Alexandra Chevalier.

Schering-Plough was advised by Gide Loyrette Nouel (Anne Tolila and Matthias Grolier) and by Hogan Lovells (Dominique Mendy) on Labor aspects.

Read the press release in French (PDF): "Dechert conseille Cenexi dans son acquisition d’un site de production pharmaceutique auprès du groupe MSD."

About Dechert

Dechert is a global specialist law firm focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients’ most important matters. Nothing stands in the way of giving clients the best of the firm’s entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.

Subscribe to Dechert Updates